Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



The 5 Most Hated Biotechs: Myraid, Sarepta, Questcor, Ziopharm, and MannKind

Looking at a company's short interest should be an integral part of an investor's due diligence. A high short interest isn't necessarily a reason shun a company, but understanding why investors are shorting the stock is important. The shorts may be wrong, but investors should be able to convince themselves of that before hitting the buy button.

In the following slideshow, you'll find info on the five most shorted biotechs on the Nasdaq -- Myraid Genetics (NASDAQ: MYGN  ) , Sarepta Therapeutics (NASDAQ: SRPT  ) , Questcor Pharmaceuticals (NASDAQ: QCOR.DL  ) , Ziopharm Oncology (NASDAQ: ZIOP  ) , and MannKind (NASDAQ: MNKD  ) -- and a brief explanation on why each company is hated so much.

A stock pick our chief investment officer loves
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Read/Post Comments (2) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 21, 2014, at 3:24 PM, razorbackndc wrote:

    It's Myriad Genetics.

  • Report this Comment On March 04, 2014, at 12:15 AM, garifolle wrote:

    Myraid Genetics ???

    You know this company well enough to say it us one of the most hated?

    Could you justify this?

    This company made me rich, and I am not from those who "hate" it.

    Another meaningless article just written to promote you paying newsletters.

    But this article does more harm then good ( I mean to Fools, not to Myriad Genetics)

    And as a Canadian, I am sick and tired to read you silly add:

    "3 Reasons to Get Out of Canadian Stocks!"

    In the past months, the TSC has done so much better then the American indices.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2843834, ~/Articles/ArticleHandler.aspx, 9/1/2015 4:45:33 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Orelli

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Today's Market

updated Moments ago Sponsored by:
DOW 16,058.35 -469.68 -2.84%
S&P 500 1,913.85 -58.33 -2.96%
NASD 4,636.11 -140.40 -2.94%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/1/2015 3:59 PM
MNKD $3.71 Down -0.08 -2.11%
MannKind Corp CAPS Rating: **
MYGN $36.65 Down -0.91 -2.42%
Myriad Genetics CAPS Rating: ***
QCOR.DL $0.00 Down +0.00 +0.00%
Questcor Pharmaceu… CAPS Rating: **
SRPT $35.21 Down -0.49 -1.37%
Sarepta Therapeuti… CAPS Rating: ***
ZIOP $8.57 Down -0.14 -1.61%
ZIOPHARM Oncology CAPS Rating: **